Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     
  • GBP/USD

    1.2491
    -0.0020 (-0.16%)
     
  • Bitcoin GBP

    51,051.51
    -717.91 (-1.39%)
     
  • CMC Crypto 200

    1,328.01
    -68.53 (-4.91%)
     
  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     
  • DOW

    38,239.66
    +153.86 (+0.40%)
     
  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     
  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

A Close Look at Ignyta’s Licensing Agreement

A Close Look at Ignyta’s Licensing Agreement

The agreement granted Ignyta exclusive global rights to develop and commercialize entrectinib. Under the license, Ignyta’s development rights are exclusive for entrectinib for the term of the agreement. The license also grants exclusive rights to Ignyta for a term of five years with respect to any product candidate that NMS might develop that has activity against the target proteins of entrectinib.